Introduction
Percutaneous transluminal coronary angioplasty followed by a stent implantation is the first technique of the revascularization. Most of these stents are manufactured using cobalt chromium coated with iridium oxide or diamond-like carbon layers to prevent the formation of an oxide layer on their surface that is fragile and mechanically unstable under flow conditions. 1 Despite the development of new coronary stent technologies, interactions of blood and cells with the implanted devices remain a serious cause of side effects. The major complications of their implantation are restenosis and late stent thrombosis (LST), which raises serious questions about their long-term safety. In-stent restenosis results from the proliferation of smooth muscle cells (SMCs). 2 Late thrombus formation mechanism has not been fully explained yet, nevertheless, LST is thought to be associated with premature cessation of antiplatelet therapy in patients, stent malapposition, late re-endothelialization of the stent struts and the nature of polymer coating. [3] [4] [5] [6] In 45% of cases, they lead to patient death.
In this context, three main approaches were developed to design safer drug-eluting stent (DES). 7 The first one is polymer-free coating. [8] [9] [10] Stent surfaces are microporous or contain cavities where drugs are loaded. Nevertheless, the release control on these stents is difficult and the velocity is often too high. 8, 11, 12 The second one consists of a biodegradable polymer coating that allows the drug-delivery during the degradation of the polymer. 10, 13 In this case, the polymer and its degradations products have to be biocompatible and not trigger any inflammatory reactions. Many biodegradable coatings were investigated. 14, 15 Alternatively, biodegradable stents were also developed. 11, 16, 17 Nevertheless, side effects such as inflammatory reactions related to their degradation products have been reported. 15 Clinical studies revealed that these bioresorbable stents led to an increased risk of stent thrombosis in comparison with DES. As a matter of fact, metallic stents appear to be the most adapted device to prevent coronary artery closure. The third approach is therefore based on a non-degradable polymer that protects the stent from corrosion. In vitro metallic stent backbone was shown to release degradation products leading to a possible allergic reaction or sensitization. 18 The polymer must be biocompatible and should promote endothelial coverage to prevent side effects in contact with blood. 5 Recent studies suggest that the faster the reendothelialisation of the stented area is, the lower the risks of inflammation and thrombus formation are. 19 The drug action and the polymeric coating materials themselves may inhibit the growth of endothelial cells, leading to disturbed vascular healing. 20 In this context, it was stated that the stent platform, the drug and the polymeric drug carrier are all targets for DES improvement. 19 Polymethacrylate polymers are widely used on medical devices for their mechanical properties and particularly the poly(n-butylmethacrylate) (PBMA) on several DES. 21 Nonetheless, it is associated with another polymer because if the polymer is used on its own, its elasticity is too low to resist to stent deformation. 21, 22 Previous works have demonstrated that a copolymer of dextran, a natural polysaccharide, along with PBMA (Dex-PBMA) exhibits elastic properties suitable for stent coating. 22 This combination promotes in vitro endothelial cell growth and inhibits the SMCs proliferation compared to PBMA alone. 23 Besides, dextran is non-toxic and has already been approved by the US Food and Drug Administration for its clinical use for example as plasma volume expander. 24 Therefore this study was undertaken to evaluate the haemocompatibility and biocompatibility of Dex-PBMA coated on glass coverslips and CoCr discs or stents, in vitro on coagulation, platelets and endothelial cells. Then more studies were performed ex vivo and in vivo in preclinical models of restenosis and intimal hyperplasia.
BioImpacts, 2019, 9(1), 25-36 27 For film preparation, 1.5 mL of 30% (w/v) of copolymers solution was poured into a 15 mm diameter Petri dishes. After solvent evaporation, drying and sterilization were performed in the same experimental conditions as described above. An 8 mm diameter circular punch purchased from Harris, Uni-Core (Redding, USA) was used to obtain round-shaped films. Then, Dex-PBMA films were washed in NaCl 0.9%.
For disc and stent associated with Tacrolimus (Dex-PBMATAC disc or stent), TAC (1 mg.mL -1 ) was dissolved in THF/water solution before Dex-PBMA in order to obtain Dex-PBMA TAC solution. Then, disc or stent was coated in the same way as Dex-PBMA disc or stent.
Evaluation of Dex-PBMA coating resistance under flow conditions
The coating resistance of Dex-PBMA stent was evaluated in vitro under dynamic conditions. For that purpose, Dex-PBMA stents (internal expanded diameter 4 mm, 8 mm long) were expended in a silicon tube Versilic ® (4 mm in internal diameter) from Nortec (St Etienne du Rouvray, France) and submitted to a coronary-physiological flow (shear rate 1000 s -1 ) in water at 37°C (n=3). During the same time-course experiment, Dex-PBMA stents were left in static condition (water, 37°C). After 7 days, samples were metalized with 5 nM of gold and observed using an environmental scanning electron microscopy (ESEM, XL30 ESEM-FEG Philips) with an accelerating voltage of 20 kV at Hivac. Water contact angle analysis Contact angles were evaluated using the sessile drop method using a DSA 10 Kruss Instrument (Villebonsur-Yvette, France). A 1 μL water droplet was dispensed on the surface, and the contact angle determination for each sample was the average value of ten measurements on different parts of the samples: CoCr discs, Dex-PBMA discs and Dex-PBMA TAC discs (n=3).
Biocompatibility tests Blood collection and platelet isolation
Human whole blood was obtained from healthy volunteers exempt from medication for at least 10 days, after full informed consent was obtained, according to the Declaration of Helsinki. All experiments were carried out with fresh peripheral blood provided by the French blood bank institute (EFS) under an agreement with the INSERM U1148 (n°12/EFS/079). Blood was collected via venipuncture into siliconized Vacutainer™ tubes from Becton Dickinson (Le Pont de Claix, France) containing buffered sodium citrate (0.12 M, nine parts blood to one part sodium citrate solution) with the first tube being discarded. Whole blood was centrifuged at 120 g for 15 minutes at room temperature to prepare platelet-rich plasma (PRP). For thrombin generation, platelet counts in PRP were adjusted to the desired concentration by dilution with autologous platelet poor plasma (PPP).
PPP was prepared by centrifugation of the blood at 2,000 g for 15 minutes. Alternatively, blood was collected on acid-citrate-dextrose anticoagulant (ACD-A) to prepare washed platelets as previously reported. 25 ) and PPP by means of the Calibrated Automated Thrombogram (CAT) method from Thrombinoscope BV (Maastricht, The Netherlands) as previously described. 27 Measurements were conducted with 80 μL PRP or PPP in a total volume of 120 µL in flat-bottom 96-well plates, containing Dex-PBMA and the CoCr discs. Thrombin generation was performed in the absence or presence of tissue factor (TF, 20 µL, 0.5 pM and 1 pM final concentration for PRP and PPP, respectively). Dedicated software from Thrombinoscope ® , Thrombinoscope BV (Maastricht, The Netherlands) enables the calculation of thrombin activity and displays thrombin activity against time. All experiments were carried out 6 times. Results were expressed in a proportion of a control Immulon 2HB well from Thermoscientific ® (Illkirch, France). The velocity index (nM.min -1 ) was calculated from CAT parameters [VI=Peak/(time to PeakLagTime)]. LagTime (LT in min) is related to the initiation phase of coagulation and correspond to the generation of 10 nM of thrombin, time to Peak (tPeak in min) and Peak (maximal dose of thrombin produced in nM) are related to the amplification phase of coagulation. Cell adhesion and proliferation on Dex-PBMA One day before experiments, ECFCs and MSCs were growth-arrested for 18 h respectively in EBM2, 2.5% FCS and MEM Glutamax. They were then washed, detached with accutase from Sigma Aldrich (St Quentin Fallavier France) and suspended in the appropriate medium. All assays were performed in triplicate. Dex-PBMA or CoCr discs were placed at the bottom of 96-well plates. As a positive control some wells were coated with gelatin 0.2% (30 µL, 20 min at RT). All samples were passivated with FCS (50 µL, 20 minutes at 37°C).
Cell isolation and preparation
For cell adhesion assay, ECFCs or MSCs cells were seeded onto disc at 25 000 cell.cm -2 in the appropriate medium. The cells were incubated either for 20 minutes or 2 hours at 37°C in 5% CO2 in a humidified incubator. After washing the disc with PBS to remove non-adherent cells, cell adhesion quantification was determined by pNPP from Sigma Aldrich (St Quentin Fallavier France) at 405 nM using a Fluostar optima from BMG Labtech (Champigny s/Marne, France).
For cell proliferation assay, ECFCs or MSCs cells were seeded on each disc at 15 000 cell.cm -2 in their respective media. The cells were incubated for 3 or 4 days at 37°C in 5% CO 2 in a humidified incubator. On day 3 and day 4, cell proliferation was evaluated by pNPP assay. In all assay, results were expressed as a ratio of gelatin control (n=3).
Bacterial adhesion on Dex-PBMA
The experimental procedure of the adhesion of Staphylococcus aureus CIP53136 obtained from Institut Pasteur (Paris, France) on Dex-PBMA film, CoCr disc and collagen (positive control) was adapted from Anagnostou et al. 28 S. aureus was used because it is the main bacteria involved in stent infection. 29 First, samples were incubated 1 hour at 37°C in FCS. The samples were then washed with PBS and then incubated with 1 mL of a suspension of S. aureus 108 colony forming units/ml (UFC/mL) concentration. After 1 hour of incubation at 37°C, samples were washed three times with PBS and incubated with 500 µL of trypsin. The removed bacteria were then spread on agar gel and cultivated overnight. Then, bacterial colonies were counted (n=3).
In vitro pharmacological drug-release studies
Dynamic perfusion systems were developed in order to study the release of a model molecule from the Dex-PBMA. The chosen molecule was tacrolimus (TAC). The circulation system was a flask containing perfusion medium -Dulbecco's Modified Eagles Medium (DMEM) from Invitrogen, ThermoFisher Scientific (Villebon sur Yvette, France) supplemented with sodium bicarbonate L-glutamine (2 mM, Invitrogen), penicillin/streptomycin (10 ml.L -1 ) from Gibco, ThermoFisher Scientific (Villebon sur Yvette, France) and FCS connected to a peristaltic pump and maintained at 37°C -in which one a stented artery was introduced. A physiological rate flow was then applied on the system (shear rate 1000 s -1 ) and 0.2 µm sterile filters allowed gas exchange. Arteries were removed from male Wistar rats (200-250 g, 8 week-old from Janvier Labs -CERJ (Le Genest St Isle, France) and cut in segments 5-7 cm length. A Dex-PBMA or Dex-PBMA TAC stent was then expanded into them (2.5 mm in diameter) and the arteries were placed into the circulating ex vivo system. 1/500th of the perfusion medium was taken every day for 6 days. A specific assay was developed to quantify the concentration of TAC released in the collected samples BioImpacts, 2019, 9(1), 25-36 29 using an immunoaffinity bead-based flow cytometric test and the xMAP ® technologies. Sheep polyclonal anti-TAC from R&D Systems (Abingdon, UK) was covalently coupled to the fluorescent color-coded beads (BDTM Cytometric Bead Array). Before the assay and to control the bead grafting, the beads were incubated with a secondary fluorescent antibody (Rabbit anti-Sheep-FITC) from Pierce (Paris, France). In order to determine TAC concentration, samples were mixed with the previously grafted beads and kept in the dark (2 hours, RT). The captured TAC was detected using specific biotinylated anti-tacrolimus secondary antibody (HyTest LTD). After wash, streptavidin-phycoerythrin (PE) detection reagent was incubated with capture bead in the dark (15 min, RT). The acquisition was achieved on BD FACS array bioanalyzer from BD Bioscience (San Jose, CA, USA). The intensity of fluorescence of yellow parameter (PE emits at 585 nm) is proportional to the amount of TAC present in samples. Standard curves of TAC (range 48-25,000 pg.ml -1 ) were run in each assay.
In vivo implantation
The procedures and the animal care complied with the "Principles of animal care" formulated by the European Union (Animal Facility Agreement n°75-18-03, 2005) and the protocol was approved by the ethical committee (authorization n°75-214, French Ministry of Agriculture).
Rat intramuscular and intra-aortic implantations
Twelve healthy male Wistar rats (9 to 11 week-old, CERJ, France) were used for the study. The rats were sedated before and during each manipulation with Pentobarbital (0.1% v/w).
Intramuscular implantation: Foreign body reaction to Dex-PBMA was first evaluated by intramuscular implantation. Dex-PBMA films were implanted in the abdominal wall of 9-weeks-old male Wistar rats and harvested after 7 and 30 days (n=3). After 48h of immersion fixation with 4% formalin, tissues were embedded with paraffin. Sections of 6 µm thickness were cut (Microm HM) from the middle part of the film, then deparaffined and stained with hematoxylin-eosin (HE) and Naphthol AS-D Chloroacetate esterase stains. The thickness of the cell cap was measured 5 times on HE histological sections, 3 sections by rats (n=3), using the soft NDP view after scans by Nanozoomer from Hamamatsu (Hamamatsu City, Japan).
Intra-aortic implantation. Dex-PBMA stent coating was then evaluating. 11-weeks-old male Wistar rats received a standard diet and aspirin in water (1 mg.mL -1 ) 72 hours before implantation to sacrifice. A 2.25 mm-diameter 8-mm-long stent was implanted through an abdominal aorta access. After a flush of the aorta with 200 U of heparin sodium from Pfizer (Paris, France), rats were sutured. An angiography was made after 30 days followed by sacrifice. Stented aortas were then harvested, fixed 72 hours with 4% formalin and methyl methacrylate-embedded (Sigma, France) protocol adapted from Rippstein et al. 30 Section of 10 µm thickness were cut from the middle part of the stent. Subsequently, sections were deplastified and stained with HE or immune-stained with alpha actin, RECA (endothelial cells) and CD-68 (macrophages -respectively MCA5781GA, clone HIS52 Bio-Rad and MCA341GA from Bio-Rad AbD Serotec (Kidlington, UK).
Implantation in a rabbit model of intimal hyperplasia
The protocol was adapted from Feldman et al. 31 Three male New Zealand White Rabbits, weighing 3.5 to 4.7 kg, were fed a 0.3% cholesterol diet, started 21 days before angioplasty. Animals were anesthetized with intramuscular ketamine 500 U, Xylazine and Vetranquil (14:8:4 v/v). All animals received heparin (1000 U) within the carotid before angioplasty. A 5F sheath was inserted in the left carotid artery. Intimal hyperplasia was induced by balloon angioplasty followed by stent implantation. Bilateral iliac artery angioplasty was performed with a 2.5-mm-diameter, 20-mm-long angioplasty balloon catheter (3 times 1-minute inflation at 8 atm). A 8-mmlong and 2.75 mm in diameter coated stent mounted over the balloon, was implanted in both iliac arteries immediately after balloon angioplasty (30-second inflation at 10 atm), resulting in frank arterial overstretch (1.2 to 1.3 stent-to-artery ratio). Arterial blood was drawn before angioplasty and at euthanasia. The concentration in TNFα was evaluated before implantation and before sacrifice using Elabscience rabbit TNFα ELISA Kit to study the effect Dex-PBMA or Dex-PBMA TAC on TNFα (Houston, USA).
Morphometric analyses of restenosis
According to Feldman et al, 31 morphometric analyses were performed using the soft NDP view after scans by Nanozoomer from Hamamatsu (Hamamatsu City, Japan). Measurement of the luminal area as well as 2 areas bounded by the internal and external elastic lamina on HE staining served to compute intimal and media areas. Three indexes of intimal growth were used: intimal area, media area and the ratio between these last ones. This experiment was carried out on rat and rabbit stented arteries.
Statistical analysis
Each experiment was carried in triplicate at least. Data are presented as mean +/-standard deviation. One-way analysis of variance (ANOVA) with Bonferroni's post hoc test was used to examine the significance of results between groups if their number where higher than 2 otherwise t-test were used. A value of P <0.05 was accepted as statistically significant.
Results

Dex-PBMA characterization
The synthesis leads to a homogeneous white powder of dextran-graft-polybutylmethacrylate copolymer (Dex-PBMA) soluble in a mixture of THF and water (92:8 v/v). The coatings of Dex-PBMA on a glass coverslip, CoCr disc and CoCr stent or moulding resulted in a transparent film, homogeneous and without cracks. Dex-PBMA deep-coating of stent covered each strut independently with very few webbing. The stent surface modifications were studied using SEM and contact-angle analysis. As shown Fig. 1A , this coating withstands to the crimping on the balloon and the deployment. After one week of incubation at 37°C and under coronary-like flow conditions, Dex-PBMA coating remained unaltered and showed a uniform polymer surface, niether pealing nor delamination was observed.
The coating wettability was evaluated by measuring water contact angles (Fig. 1B) . CoCr is less hydrophobic (θ=88.7° ± 2.2) than Dex-PBMA with or without Tacrolimus (respectively θ=98.5° ± 0.4 and 99° ± 2.9, P = 0.0078).
Bacterial adhesion
As shown Fig. 2 , Staphylococcus aureus was lower on Dex-PBMA than on CoCr (ratio 11, P < 0.005) and control collagen (ratio 4.5, P < 0.05). In contrast, more bacteria adhered on CoCr than on control (ratio 4.7, P < 0.005).
Adhesion of platelets and thrombin generation on Dex-PBMA
In static condition, platelet adhered less on Dex-PBMA (Fig. 3A) than on the positive control collagen (ratio 2.7, P < 0.0001) or on CoCr (ratio 1.39, P < 0,01). The SEM images showed less platelet activation on the copolymer than on the bare metal. Non-activated platelets are diskshaped. Once activated, they first take a spherical shape as observed on Dex-PBMA disk (Fig. 3A) before spreading and giving out extensions such as filopodia that can be observed on CoCr surface. 32 In dynamic conditions, no platelet adhered on Dex-PBMA (Fig. 3B) . Dex-PBMA coating does not promote platelet adhesion and activation in our experimental conditions.
Thrombin generation was performed on Dex-PBMA and CoCr. In PPP, the velocity index of thrombin generation was 1.9 fold lower on Dex-PBMA disc than on CoCr disc (Fig. 3C , P < 0.01) in presence of Tissue Factor. There were no differences between the two surfaces for thrombin generation when the assay was performed in PPP without Tissue Factor (Fig. 3C ) or in PRP with or without Tissue Factor (data not shown).
Cell adhesion and proliferation onto Dex-PBMA
ECFCs and MSCs adhered less on Dex-PBMA disc than on CoCr disc (Fig. 4) . Non-significant differences were obtained for intermediate adhesion (20 min incubation time) whereas for focal adhesion (2 hours incubation time), 2.4 less ECFCs (Fig. 4A , P < 0.0005) and 1.6 less MSCs (Fig.  4B , P < 0.05) adhered on Dex-PBMA compared to CoCr discs. The same trends were observed for cell proliferation (Fig. 4C and Fig. 4D ). The proliferation of ECFCs and MSCs was greater on CoCr disc than on Dex-PBMA. In both cellular type and surfaces, the proportion of cells compared to control coating of gelatin decrease after 4 days. Thus, CoCr or Dex-PBMA surfaces cause cells to grow more slowly than on control gelatin wells. Fig. 5 shows the cumulative TAC release profile from ex vivo stented arteries. An extreme burst release was observed corresponding to 5 ng/mL (50%) after 3 hours, followed by a steady state reaching 10 ng/mL over 4 days.
Release of tacrolimus from Dex-PBMA
In vivo implantation of Dex-PBMA Rat intramuscular and intra-aortic implantations
Dex-PBMA films were first implanted in rat abdominal wall to evaluate the tissue reactions after 7 and 30 days (Fig. 6) . As shown on HE staining (Fig. 6A) , a tissue surrounded the film at day 7 with a thickness of 40 ± 12 µm that remain stable at day 30 (47 ± 12 µm). The low level of Naphthol AS-D Chloroacetate staining indicated BioImpacts, 2019, 9(1), 25-36 31 that no neutrophil granulocytes were detected in the tissue (Fig. 6B) . The capsule is thus mainly composed by collagen without any evidence of inflammatory reaction or necrosis. Dex-PBMA was then evaluated on a coated stent in rat abdominal aorta. Immediately after implantation, no acute thrombosis was observed. After 30 days, all Dex-PBMA or control CoCr stent implanted rats (n=6) survived. At day 30, angiographies confirmed that all arteries were patent. As shown in Fig. 7 , no thrombus was found in Dex-PBMA or CoCr stented arteries. Nevertheless, a small intimal hyperplasia was observed both on Dex-PBMA and CoCr stents whereas no significant differences were noticed in the areas of intima (0.54 ± 0.007 mm 2 vs. 0.50 ± 0.06 mm 2 ) and media (0.40 ± 0.04 mm 2 vs. 0.43 ± 0.02 mm 2 ) on CoCr stent and Dex-PBMA stent (Fig. 7A) . No macrophages were emphasized in the arterial wall (CD 68 staining, Fig. 7B ). The neointima was mainly composed of SMCs (α-actin staining). This SMC layer was cover by an endothelial layer (RECA staining) on Dex-PBMA as well on CoCr stents (Fig. 7B) . As observed in vitro, no platelets adhered on Dex-PBMA and we noticed the absence of thrombus formation.
Implantation in a rabbit model of intimal hyperplasia
Dex-PBMA or Dex-PBMA TAC stents were evaluated in a pathological model of neointimal hyperplasia. After 30 days the iliac arteries were patent. Hematoxylineosin staining indicated a neointima (Fig. 8A) . The measurements emphasized a higher ratio of intima and media areas on Dex-PBMA stent than on CoCr stent BioImpacts, 2019, 9(1), 25-36 32 (2.39 vs 1.90). Nevertheless, with Dex-PBMA TAC this ratio decreased (1.60 vs 2.39). On the other hand, TNF-α blood concentration used as a biomarker between before and 30 days after implantation increased in CoCr stent implanted rabbit (+15.6 pg/mL), and remain stable for Dex-PBMA stent implanted rabbit (+0.53 pg/mL) and decreased for Dex-PBMA TAC stent implanted rabbit (-4.87 pg/mL) (Fig.  8B ).
Discussion
Implantable medical devices integration is a challenge. Their biocompatibility relates to the specific interaction between the biomaterial, blood components and tissue vessel. In previous studies, we demonstrated that Dex-PBMA polymer coating improves in vitro the endothelial cell coverage and limits the SMC proliferation involved in the stent restenosis. 22, 23 Current complications on stent are not only due to stent restenosis but also to LST. 21, 33, 34 Both stent geometry and position play a role in stent thrombosis outbreak. 4, 35 Stent coating itself is a major factor in its interactions with blood and vascular wall and its quality can be highly variable. 35 Indeed, implanted commercial coated stent showed uncoated areas, craters, webbing or cracks. 36, 37 Coating integrity and mechanical resistance during implantation and indwell have an impact on long-term stent safety.
14 In the present work, Dex-PBMA stent struts were fully and homogeneously coated. The coating resists to both crimping and stent deployment as well as under the shear stress of physiological flow. This behavior prevents polymer fragmentation and embolization in blood circulation.
Several studies underline the importance of a rapid re-endothelialization of the stented area. 19 In humans, re-endothelialization is due to the proliferation and migration of adjacent endothelial cells (ECs), but also to the contribution of endothelial progenitors cells in the circulation blood that differentiate in ECs. 38, 39 For instance, anti-CD34-bio-engineered stents were developed to reduce thrombogenicity. 13, 40, 41 Because ECFCs that differentiated in vitro from endothelial progenitors and MSCs allows wound healing, we thus investigated their adhesion and growth on Dex-PBMA surface. Measurement of cell adhesion, viability and proliferation revealed no cytotoxic effect.
In previous studies, a lower hydrophobic copolymer improves in vitro the endothelial cell coverage and limits the SMC proliferation involved in stent restenosis. 22, 23 This difference could be explained by the control of cerium concentration during the synthesis. Because cerium is able to increase prothrombin formation, coagulation time and induce a proinflammatory cytokine secretion, 42, 43 cerium concentration was decreased from 0.2 M to 0.05 M and additional filtration steps were performed. Elementary analysis confirmed the decrease of the residual cerium concentration from 1.73 ± 0.15% to 0.069 ± 0.033%. The hydrophobicity of Dex-PBMA can explain the observed differences in vitro. Numerous works demonstrated the impact of the surface wettability on cell adhesion and proliferation. 44 Nevertheless, this effect is lowered in vivo, by plasmatic protein deposition, mainly the albumin, which occurred immediately after the device implantation, 45, 46 increasing the wettability and favoring the material integration as observed in our in vivo study. Indeed, in both rat healthy aorta and rabbit pathological models, hyperplasia on Dex-PBMA stents were limited and comparable to CoCr Stents. Moreover, immunostaining highlighted a new endothelial cell layer in rats.
As the transcutaneous way of stent implantation may involve a bacterial infection risk and some lethal cases, bacterial adhesion was evaluated. 29 However, dextran is known to favor bacterial adhesion and growth, 47 and functionalized polymethyl methacrylate-based polymers were shown to prevent it. 28 S. aureus adhesion to Dex-PBMA CoCr disk was thus assessed and was equivalent to the negative control. In contrast, a higher rate of bacterial adhesion was observed on bare CoCr disk, probably due to the electropolishing surface treatment used for clinical stent preparation, 48 which generates micro-scratches favoring bacterial adhesion on the surface. In our experimental conditions, our Dex-PBMA coating was shown to prevent bacterial adhesion.
Hemocompatibility is identified as a key milestone for a vascular device development. Platelet adhesion and blood coagulation are modulated by material surface. [49] [50] [51] As an example, in polylactic acid and magnesium scaffolds or silicone rubbers material used for the biomedical membrane, the thrombosis remains the main complication. 35, 52, 53 The Platelet adhesion was thus evaluated as reflect of primary hemostasis. We studied either in vitro static and dynamic platelets adhesion as well as thrombin generation on Dex-PBMA surfaces. In static and dynamic conditions few platelets adhered on the surface coated with Dex-PBMA as compared to the bare metal CoCr. We then quantify thrombin generation, which allows us to check the influence of our copolymer on all the coagulation pathways. Dex-PBMA copolymer reduces the formation of thrombin in plasma when coated on CoCr, reflecting an inhibition of the coagulation pathway. Thus, our results showed that Dex-PBMA copolymer is hemocompatible and do not trigger platelets adhesion and activation, as well as blood coagulation.
Moreover in vivo, both in rat and rabbit models, histological results show the absence of acute thrombosis immediately after the implantation or at the time of explantation. Therefore Dex-PBMA exhibits key factors for hemocompatibility.
Since several strategies are currently used to improve the stent efficiency by adding drug in the coating of the whole structure, the abluminal face or by introducing it into the micro-cavities, 11, 54 we investigated the possibility to use dextran-PBMA polymer as a drug delivery platform. Tacrolimus, a macrolide molecule loaded in several stents polymer stent coating, 8 was chosen as a drug model. Under flow, we demonstrated that Dex-PBMA coating could act as a drug eluting platform and release TAC in the medium. A burst release profile (50%) within 3 hours and a steady state over 4 days were observed. These results show a release profile similar to pharmacokinetic profiles of DESs such as the clinical Janus CarbosStent that releases TAC in the vascular wall tissue within the first hours, and then reaches the steady-state within 6 days. 8, 55 The release profile depends on the initial coating as well as the loaded concentration in the stent. 56 The duration of Tacrolimus release from Dex-PBMA Tac can be improve using multilayer of Dex-PBMA coating strategy as observed with the Cypher ®21 or the Infinnium ® stents. 15 In our conditions, the low loading level of the drug could explain the results observed in vivo in restenosis rabbit model where no difference was seen between Dex-PBMA TAC and Dex-PBMA stents. Another study should be devoted in the future to increase the amount of drug and then evaluate its efficiency. The in vivo implantation of a material and its degradation induce the local repair process, which involves the inflammation and the remodeling process. [57] [58] [59] From the in vivo results, neither esterase staining nor TNFα blood cytokine modification was found. No pathologic inflammatory reaction was observed in the intramuscular position or in the aorta. Furthermore, the fibrous cap thickness is important in the case of drug delivery. 57 A thicker cap decreases drug release. Dex-PBMA shows a moderate thickness of the fibrous cap as compared to other drug delivery platforms. 60 Therefore Dex-PBMA can therefore be proposed as an interesting local drug delivery platform.
Conclusion
The present study shows that Dex-PBMA exhibited properties suitable for stent coating, resisted to mechanical forces required for crimping coating processes, remained undamaged under flow conditions and could release a drug. Dex-PBMA exhibited moderate platelet adhesion and did not trigger thrombin generation in vitro and allowed endothelial progenitor and MSCs proliferation. In vivo Dex-PBMA i) was efficient to promote endothelial coverage 30 days after stent implantation that might prevent side effects in contact with blood, ii) prevented pathological inflammatory reaction in a rabbit model of intimal hyperplasia. Dex-PBMA represents therefore a What is the current knowledge? √ PBMA polymers are used in the commercial stent coating √ Dex-PBMA with suitable elastic properties were developed as a stent coating. √ The nature of the polymer coating is involved in the major complications after stent implantation: restenosis and LST. What is new here? √ In vitro under physiological flow, Dex-PBMA is hemocompatible and do not trigger platelet adhesion and activation as well as blood coagulation √ Dex-PBMA stent coating remained unaltered and could release Tacrolimus under coronary-like flow conditions. √ Dex-PBMA exhibits biocompatibility properties in vivo in aortic stent rat model and in pathological neointimal hyperplasia rabbit model.
Research Highlights
new opportunity and an interesting alternative for coating implantable medical devices at the interface with the blood.
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